Long-term tolerance of zidovudine treatment was retrospectively analysed in 97 patients with AIDS or AIDS-related complex. After one year of treatment 68% and after two years 87% of the patients had had at least one dose adjustment during their course of therapy.Myelotoxicity was the most common cause (58% of all cases) of dose reductions and therapy interruptions (dose adjustments). At the time ofthe first dose adjustment 33 patients (34%) were suffering from anaemia (Hb < 6-0 g/dl), 20 patients (21%) from leukopenia (leukocytes < 1-5 x 10'), and 10 patients (10%) from thrombocytopenia (thrombocytes <75 x 10'). Fifty-six patients (57%) needed one or more blood transfusions during therapy. The median time from the start of therapy to the time ofthe first dose adjustment was 14 (range: 2-64) weeks in patients who had a first dose adjustment because of anaemia without coexisting leukopenia or thrombocytopenia, and 37 (range: 6-85) weeks in patients who had a first dose adjustment because of leukopenia without co-existing anaemia or thrombocytopenia (p = 0-01). Peripheral blood CD4 positive lymphocyte counts <100/mm3, anaemia, and CDC classification IV-C1 at the start of treatment were associated with a need for an early dose modification or blood transfusion rather than the need for dose modification per se.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.